BlackRock Advisors’s Myriad Genetics MYGN Stock Holding History

BlackRock Advisors’s Portfolio MYGN Stock Details MYGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	$1.48M	Sell	88,952 -48,498	-35%	-$877K	﹤0.01%	1664
2016 Q3	$2.83M	Buy	137,450 +803	+0.6%	+$20.4K	﹤0.01%	1337
2016 Q2	$4.18M	Buy	136,647 +1,839	+1%	+$63.9K	﹤0.01%	1174
2016 Q1	$5.05M	Buy	134,808 +5,152	+4%	+$194K	0.01%	1095
2015 Q4	$5.6M	Buy	129,656 +23,171	+22%	+$979K	0.01%	1067
2015 Q3	$3.99M	Buy	106,485 +7,596	+8%	+$270K	﹤0.01%	1172
2015 Q2	$3.36M	Buy	98,889 +87,999	+808%	+$2.99M	﹤0.01%	1099
2015 Q1	$386K	Sell	10,890 -6,804	-38%	-$244K	﹤0.01%	2274
2014 Q4	$603K	Sell	17,694 -3,819	-18%	-$136K	﹤0.01%	1859
2014 Q3	$830K	Sell	21,513 -43,619	-67%	-$1.63M	﹤0.01%	1560
2014 Q2	$2.54M	Sell	65,132 -1,901,809	-97%	-$70.8M	﹤0.01%	1116
2014 Q1	$67.3M	Buy	1,966,941 +79,355	+4%	+$2.46M	0.07%	288
2013 Q4	$39.6M	Buy	1,887,586 +52,941	+3%	+$1.34M	0.04%	393
2013 Q3	$43.1M	Buy	1,834,645 +218,102	+13%	+$6.2M	0.04%	355
2013 Q2	$43.4M	Buy	+1,616,543	New	+$46.9M	0.05%	346

Other funds holding MYGN

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

FCM

Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

BlackRock Advisors's MYGN Position: Q4 2016 in Review

BlackRock Advisors reduced its Myriad Genetics (MYGN) stake by 35% in Q4 2016, selling an estimated $877K and leaving 88,952 shares worth $1.48M. The position accounts for ﹤0.01% of the portfolio, ranked #1664.

BlackRock Advisors first reported a position in MYGN in Q2 2013 and has held it in 15 quarters since. The position peaked at $67.3M in Q1 2014. 223 funds tracked by Wall St. Rank hold MYGN as of Q4 2016.

BlackRock Advisors held 88,952 shares of Myriad Genetics worth $1.48M as of Q4 2016.
BlackRock Advisors sold 48,498 Myriad Genetics shares in Q4 2016, an estimated $877K.
Myriad Genetics made up ﹤0.01% of BlackRock Advisors's portfolio in Q4 2016, its #1664 holding.
BlackRock Advisors first reported a position in Myriad Genetics in Q2 2013 and has held it in 15 quarters since.
BlackRock Advisors's Myriad Genetics position peaked at $67.3M in Q1 2014.
223 funds tracked by Wall St. Rank held Myriad Genetics as of Q4 2016.

Based on BlackRock Advisors's 13F filing for Q4 2016, filed 10 Feb 2017.